Yewmaker Medicines Ltd 13221802 false 2023-07-01 2024-06-30 2024-06-30 The principal activity of the company is development of sustainable healthcare products Digita Accounts Production Advanced 6.30.9574.0 true true 13221802 2023-07-01 2024-06-30 13221802 2024-06-30 13221802 bus:OrdinaryShareClass1 bus:CumulativeShares 2024-06-30 13221802 core:CurrentFinancialInstruments 2024-06-30 13221802 core:CurrentFinancialInstruments core:WithinOneYear 2024-06-30 13221802 core:FurnitureFittingsToolsEquipment 2024-06-30 13221802 bus:SmallEntities 2023-07-01 2024-06-30 13221802 bus:AuditExemptWithAccountantsReport 2023-07-01 2024-06-30 13221802 bus:AbridgedAccounts 2023-07-01 2024-06-30 13221802 bus:SmallCompaniesRegimeForAccounts 2023-07-01 2024-06-30 13221802 bus:RegisteredOffice 2023-07-01 2024-06-30 13221802 bus:Director1 2023-07-01 2024-06-30 13221802 bus:OrdinaryShareClass1 bus:CumulativeShares 2023-07-01 2024-06-30 13221802 bus:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 13221802 bus:Agent1 2023-07-01 2024-06-30 13221802 core:FurnitureFittingsToolsEquipment 2023-07-01 2024-06-30 13221802 core:OfficeEquipment 2023-07-01 2024-06-30 13221802 countries:England 2023-07-01 2024-06-30 13221802 2023-06-30 13221802 core:FurnitureFittingsToolsEquipment 2023-06-30 13221802 2022-07-01 2023-06-30 13221802 2023-06-30 13221802 bus:OrdinaryShareClass1 bus:CumulativeShares 2023-06-30 13221802 core:CurrentFinancialInstruments 2023-06-30 13221802 core:CurrentFinancialInstruments core:WithinOneYear 2023-06-30 13221802 core:FurnitureFittingsToolsEquipment 2023-06-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 13221802

Yewmaker Medicines Ltd

Annual Report and Unaudited Abridged Financial Statements

for the Year Ended 30 June 2024

image-name
 

Yewmaker Medicines Ltd

Contents

Company Information

1

Accountants' Report

2

Abridged Balance Sheet

3

Notes to the Unaudited Abridged Financial Statements

4 to 6

 

Yewmaker Medicines Ltd

Company Information

Director

Dr Sabera Nazneen Rahman

Registered office

Unit 3, Upp Hall Farm
Salmons Lane
Colchester
Essex
CO6 1RY

Accountants

Integer
Unit 3, Upp Hall Farm
Salmons Lane
Colchester
Essex
CO6 1RY

 

Chartered Accountants' Report to the Director on the Preparation of the Unaudited Statutory Accounts of
Yewmaker Medicines Ltd
for the Year Ended 30 June 2024

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Yewmaker Medicines Ltd for the year ended 30 June 2024 as set out on pages 3 to 6 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at
http://www.icaew.com/regulation.

This report is made solely to the Board of Directors of Yewmaker Medicines Ltd, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of Yewmaker Medicines Ltd and state those matters that we have agreed to state to the Board of Directors of Yewmaker Medicines Ltd, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Yewmaker Medicines Ltd and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Yewmaker Medicines Ltd has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and loss of Yewmaker Medicines Ltd. You consider that Yewmaker Medicines Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Yewmaker Medicines Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

Integer
Unit 3, Upp Hall Farm
Salmons Lane
Colchester
Essex
CO6 1RY

21 November 2024

 

Yewmaker Medicines Ltd

(Registration number: 13221802)
Abridged Balance Sheet as at 30 June 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

188

510

Current assets

 

Debtors

157,378

32,818

Cash at bank and in hand

 

441,635

269,414

 

599,013

302,232

Prepayments and accrued income

 

-

835

Creditors: Amounts falling due within one year

(9,362)

(29,983)

Net current assets

 

589,651

273,084

Total assets less current liabilities

 

589,839

273,594

Accruals and deferred income

 

(577,042)

(244,073)

Net assets

 

12,797

29,521

Capital and reserves

 

Called up share capital

5

1,000

1,000

Retained earnings

11,797

28,521

Shareholders' funds

 

12,797

29,521

For the financial year ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

All of the company’s members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

Approved and authorised by the director on 21 November 2024
 

.........................................
Dr Sabera Nazneen Rahman
Director

 

Yewmaker Medicines Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 30 June 2024

1

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Yewmaker Medicines Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 30 June 2024

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office Equipment

Straight line, 3 years

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

 

Yewmaker Medicines Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 30 June 2024

2

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 3 (2023 - 3).

3

Loss before tax

Arrived at after charging/(crediting)

2024
£

2023
£

Depreciation expense

322

321

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 July 2023

966

966

At 30 June 2024

966

966

Depreciation

At 1 July 2023

456

456

Charge for the year

322

322

At 30 June 2024

778

778

Carrying amount

At 30 June 2024

188

188

At 30 June 2023

510

510

5

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

Ordinary shares of £1 each

1,000

1,000

1,000

1,000